1-11 of 11
Bhavik J Pandya, PharmD
Close
Sort by
Journal Articles

Real-World Use of FLT3-TKIs in R/R FLT3-M utated AML in the United States

David L. Grinblatt, MD, Bhavik J. Pandya, PharmD, Wei Han, PhD, Loretta Sullivan, MD MPH, Qi Feng, PhD MS, Nancy Hedlund, PhD MBA, RPh
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-136391
Published: 2020
Journal Articles

Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes

Amer M. Zeidan, MBBS, MHS, Adrienne M. Gilligan, PhD, Santosh Gautam, PhD, David L. Grinblatt, MD, Dina Elsouda, Loretta Sullivan, MD MPH, Bhavik J. Pandya, PharmD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-136366
Published: 2020
Journal Articles

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3 -Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Hongbo Yang, PhD, Andy Garnham, MSc, Manasee V. Shah, MPH, Amer M. Zeidan, MBBS, MHS
Journal: Blood
Blood (2020) 136 (Supplement 1): 7.
https://doi.org/10.1182/blood-2020-136184
Published: 2020
Journal Articles

Pain and Opioid Use in Patients with FLT3 Mutation-Positive Relapsed/Refractory AML: A Subanalysis of Patient-Reported Outcomes from the Admiral Trial

David Cella, PhD, Ellen Ritchie, MD, Arnaud Pigneux, MD PhD, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V. Shah, MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-134389
Published: 2020
Journal Articles

The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3 -Mutated ( FLT3 mut+ ) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Ellen K. Ritchie, MD, David Cella, PhD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 1332.
https://doi.org/10.1182/blood-2019-123779
Published: 2019
Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3859.
https://doi.org/10.1182/blood-2019-123819
Published: 2019
Journal Articles

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

David Cella, PhD, Ellen K. Ritchie, MD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3850.
https://doi.org/10.1182/blood-2019-123790
Published: 2019
Journal Articles

Streamline - Study of Relapse or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study

Amer M. Zeidan, MBBS, MHS, Adrienne Gilligan, PhD, Santosh Gautam, Nan Hu, David L. Grinblatt, Bhavik J. Pandya, PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5082.
https://doi.org/10.1182/blood-2019-123535
Published: 2019
Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 5085.
https://doi.org/10.1182/blood-2019-123811
Published: 2019
Journal Articles

Economic Burden of Treatment Episodes in Acute Myeloid Leukemia (AML) Patients in the US: A Retrospective Analysis of a Commercial Payer Database

Bruno C Medeiros, MD, Bhavik J Pandya, PharmD, Chi-Chang Chen, PhD, Eric S. Groves, MD PhD, Cat N. Bui, PhD, Laura Elise Horvath, MD, Rolin L. Wade, RpH, MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 4694.
https://doi.org/10.1182/blood.V130.Suppl_1.4694.4694
Published: 2017
Journal Articles

Real-World Occurrence of Symptoms and Toxicities and Associated Cost Implications in Acute Myeloid Leukemia (AML) Treatment Episodes: A Retrospective Database Analysis in the US

Bhavik J Pandya, PharmD, Bruno C Medeiros, MD, Chi-Chang Chen, PhD, Samuel Wilson, PhD, Eric S. Groves, MD PhD, Laura Elise Horvath, MD, Rolin L. Wade, RpH, MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 2118.
https://doi.org/10.1182/blood.V130.Suppl_1.2118.2118
Published: 2017